ECTRIMS 2019 Conference Review

In this review:

Physicians’ perspectives on secondary progressive MS
Misdiagnosis of multiple sclerosis
Time to MS diagnosis with different diagnostic criteria
Long-term outcomes in RoMS with low disability
Impact of stopping diseasemodifying therapy in MS
Long-term ocrelizumab for relapsing MS
Natalizumab vs fingolimod in RRMS subgroups
5- and 7-year prognostic value of new effectiveness measures in RRMS
Siponimod for active SPMS
SPMS after cladribine

Please login below to download this issue (PDF)